CN110713521A - Polypeptide CAK18N and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis - Google Patents
Polypeptide CAK18N and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis Download PDFInfo
- Publication number
- CN110713521A CN110713521A CN201911014535.3A CN201911014535A CN110713521A CN 110713521 A CN110713521 A CN 110713521A CN 201911014535 A CN201911014535 A CN 201911014535A CN 110713521 A CN110713521 A CN 110713521A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- liver
- hepatocyte
- apoptosis
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Polypeptide CAK18N and its application in promoting liver regeneration and inhibiting hepatocyte apoptosis are provided. The invention discloses a polypeptide and application thereof in promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis. Compared with the amino acid sequence shown in SEQ ID NO. 1, the amino acid sequence of the polypeptide capable of promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis has the sequence consistency of more than 16/18, the length of the polypeptide is 18 amino acids, and the polypeptide has the advantages of small molecular weight, easy synthesis, low immunogenicity and the like, so the polypeptide has wide application prospect in treatment of liver diseases.
Description
Technical Field
The invention relates to the technical field of cell proliferation and apoptosis, in particular to a polypeptide CAK18N and application thereof in promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis.
Background
The liver is the largest internal organ in the human body (about 2.5% of the total mass of the human body), and is also the central metabolic organ. The major contributors to liver function are parenchymal cells, which account for 80% of the total liver cells. The liver cells play a series of roles including plasma production, carrier protein synthesis, detoxification of digests, conjugation and hormone secretion, regulation of synthesis and metabolism of blood lipids and amino acids, and the like.
Apoptosis (apoptosis) is an active suicide process of cells in specific environments. Apoptosis was two different patterns of apoptosis and death observed by Kerr et al in 1972 when studying liver ischemia. The cell apoptosis is characterized by cell shrinkage, cellular bulge of cell membrane, formation of apoptotic bodies, degradation of nuclear fragments and nuclear DNA and other abnormal phenomena. Apoptosis is a major feature of pathological changes of many diseases in clinic, and particularly in liver diseases, apoptosis of liver cells is an important factor causing liver damage. Hepatocyte apoptosis plays an important role in the mechanism of liver pathology, and disruption of death receptor pathways is considered to be one of the important causes for triggering the development of acute/chronic liver injury. In recent years, researches show that the apoptosis of liver cells is widely involved in pathological processes of various liver diseases, including liver failure, viral hepatitis, hepatic fibrosis, liver cirrhosis, alcoholic liver diseases, non-alcoholic fatty liver diseases, autoimmune liver diseases and the like.
Liver Failure (LF) is a serious liver damage caused by various factors such as virus, drug, alcohol, etc., causing serious dysfunction or decompensation of detoxification, excretion, synthesis, etc., and a group of clinical symptoms mainly manifested by blood coagulation dysfunction, severe jaundice, ascites, hepatic encephalopathy, even gastrointestinal hemorrhage, etc., with extremely high mortality rate, which is one of the clinically common critical conditions in the department of hepatopathy. According to the difference of pathological features and disease processes, 2012 edition of guidelines for liver failure diagnosis and treatment classifies liver failure into Acute Liver Failure (ALF), subacute liver failure (SALF), chronic-on-chronic liver failure (ACLF) and Chronic Liver Failure (CLF). Liver failure is clinically critical and still lacks specific drugs with definite curative effects so far, so that the liver failure becomes one of the worldwide intractable diseases, and although artificial liver and liver transplantation are effective treatment methods, the treatment methods cannot be widely popularized and used in China due to the expensive cost, shortage of liver sources, rejection and the like. There is an urgent need for new drugs and methods for treating the above-mentioned liver diseases.
The CAK18N is a polypeptide containing 18 amino acids, and reports show that the CAK18N can inhibit angiogenesis induced by Vascular Epidermal Growth Factor (VEGF), and can be used for treating diseases such as tumor, wet macular degeneration and the like (see the Chinese patent CN109593117A), but reports of the CAK18N for promoting hepatocyte regeneration and inhibiting hepatocyte apoptosis are not available so far.
Disclosure of Invention
Based on the above problems, the present invention aims to overcome the defects of the prior art and provide a polypeptide capable of promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis.
In order to achieve the purpose, the technical scheme adopted by the invention comprises the following aspects:
the present invention provides a polypeptide, the amino acid sequence of which has a sequence identity of more than 16/18 compared to the amino acid sequence shown in SEQ ID NO. 1. It should be noted that, compared with the amino acid sequence shown in SEQ ID No. 1, the sequence identity of the claimed polypeptide sequence may be 16/18, 17/18 or 18/18, but is not limited to 16/18 or more, and may also be 15/18 or 14/18, so long as the corresponding polypeptide has the effect of promoting hepatocyte proliferation or can inhibit hepatocyte apoptosis, which all fall within the protection scope of the present invention.
Furthermore, the amino acid sequence of the polypeptide is shown as SEQ ID NO. 1.
Further, the polypeptide has terminal modification, and the terminal modification is N-terminal acetylation modification or/and C-terminal amidation modification.
In another aspect, the present invention provides the use of the above-mentioned polypeptide or a salt thereof for the preparation of a medicament for promoting hepatocyte proliferation or treating a disease caused by hepatocyte apoptosis.
Further, the salt is acetate, hydrochloride or phosphate of the polypeptide.
Further, the disease caused by the apoptosis of liver cells is liver failure, viral hepatitis, liver fibrosis, liver cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease or autoimmune liver disease. More preferably acute liver failure.
Further, the promotion of hepatocyte proliferation is the promotion of liver regeneration in vivo or the promotion of hepatocyte growth in vitro.
In still another aspect, the present invention provides a medicament for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis, which comprises the above-mentioned polypeptide or a salt thereof. Further, the salt is acetate, hydrochloride or phosphate of the polypeptide.
Further, the disease caused by hepatocyte apoptosis is acute liver failure.
Further, the promotion of hepatocyte proliferation is the promotion of liver regeneration in vivo or the promotion of hepatocyte growth in vitro.
Further, the medicament is in a liquid dosage form or a freeze-dried powder. Still further, the medicament further comprises a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be routinely selected by those skilled in the art according to the dosage form of the drug and the like. When the drug is in a liquid dosage form, administration can be by intravenous or subcutaneous injection.
In conclusion, the beneficial effects of the invention are as follows:
the invention provides a polypeptide CAK18N capable of promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis, which is 18 amino acids in length and has the advantages of small molecular weight, easy synthesis, low immunogenicity and the like, so the polypeptide has wide application prospect in liver disease treatment.
Drawings
FIG. 1 is an HPLC chromatogram of the polypeptide CAK18N of the present invention;
FIG. 2 is a diagram showing the result of detecting the activity of the polypeptide CAK18N of the present invention in promoting hepatocyte proliferation;
FIG. 3 is a diagram showing the result of detecting the activity of the polypeptide CAK18N of the present invention in inhibiting hepatocyte apoptosis.
Detailed Description
The inventor of the application conducts experimental screening on a large number of polypeptides in the prior art, and unexpectedly finds that the polypeptide CAK18N not only can promote hepatocyte proliferation, but also can inhibit hepatocyte apoptosis.
In some embodiments, the present invention provides a polypeptide CAK 18N/salts thereof and their uses that promote hepatocyte proliferation and/or inhibit hepatocyte apoptosis. Furthermore, the amino acid sequence of the polypeptide CAK18N for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis is shown in SEQ ID NO. 1.
In some embodiments, the salt comprises an acetate, hydrochloride, or phosphate salt of the polypeptide.
In some embodiments, the polypeptide is terminally modified. Further, the terminal modification is an N-terminal acetylation modification or a C-terminal amidation modification.
In some embodiments, the present invention also provides the use of the above-described polypeptide or a salt thereof for the preparation of a medicament for promoting hepatocyte proliferation or treating a disease caused by hepatocyte apoptosis. Further, the medicament is in a liquid dosage form or a freeze-dried powder. Further, the disease caused by the apoptosis of liver cells is liver failure, viral hepatitis, liver fibrosis, liver cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease or autoimmune liver disease. More preferably, the liver failure is acute liver failure.
In some embodiments, the promoting hepatocyte proliferation is promoting liver regeneration in vivo or promoting hepatocyte growth in vitro.
The invention also provides a medicament for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis, which comprises the polypeptide or a salt thereof.
Preferably, the medicament is in a liquid dosage form or a lyophilized powder.
Preferably, the promotion of hepatocyte proliferation is promotion of liver regeneration in vivo or promotion of hepatocyte growth in vitro.
Preferably, the medicament further comprises a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be routinely selected by those skilled in the art according to the dosage form of the drug and the like.
When the drug is in a liquid dosage form, administration can be by intravenous or subcutaneous injection.
The inventor of the application proves that the polypeptide CAK18N shown in SEQ ID NO. 1 has the activities of promoting hepatocyte proliferation and inhibiting hepatocyte apoptosis through in vitro cell experiments, so that the polypeptide can be used for promoting hepatocyte proliferation or treating diseases caused by hepatocyte apoptosis. Research shows that the diseases of hepatocyte apoptosis include liver failure, viral hepatitis, cholestatic liver injury, alcoholic liver injury, non-alcoholic steatohepatitis, cirrhosis, toxin-or drug-mediated liver injury and the like, and the polypeptide of the present invention has the activity of inhibiting hepatocyte apoptosis, so the polypeptide can be used for treating the diseases.
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments. The reagents or methods used in the present invention are those conventional in the art unless otherwise specified.
EXAMPLE 1 polypeptide Synthesis
The polypeptide CAK18N for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis is synthesized by a solid phase synthesis process, the purity is more than 98 percent (figure 1), and 500mg is synthesized; the amino acid sequence is shown in SEQ ID NO. 1.
Example 2 detection of Activity of the polypeptide CAK18N in promoting hepatocyte proliferation in vitro
In this example, the human liver cell line LO2 was purchased from ATCC.
The method for detecting the activity of the polypeptide CAK18N in promoting the proliferation of the liver cells in vitro in example 1 comprises the following steps:
the LO2 cells were recovered by conventional method, and then placed at 37 deg.C under 5% CO2In the incubator, DMEM complete medium containing 10% FBS and 1% double antibody was used for culture. Digesting with trypsin-EDTA when the cells are full to about 85% of the bottom of the bottle, adding DMEM complete culture medium, gently blowing to obtain cell suspension, adjusting cell concentration, inoculating into 96-well plate, each well is 100 μ L, and placing at 37 deg.C and 5% CO2Culturing in an incubator for later use.
Will logStage LO2 was inoculated into 96-well plates for 24h at 5000/well with better density as previously explored. The treatment groups were divided into a normal control group, a model control group, a CAK18N low dose (0.1. mu.g/mL), medium dose (1. mu.g/mL), high dose (10. mu.g/mL) and positive control group, each group having 6 duplicate wells. After 24h of incubation, the medium was aspirated and 800. mu. M H added to each group2O2The working solution was applied to the cells for 3h, and the normal control group was controlled by adding the same volume of medium. Washing with PBS for 2 times, adding corresponding medicated culture medium into each test group, adding normal culture medium into normal control group and model control group as control, adding 1mM acetylcysteine (NAC) into positive control group, and culturing for 24 hr. The 96-well plate was removed, the drug-containing medium was aspirated, washed 2 times with PBS, and 100. mu.L of DMEM medium containing 10% CCK-8 solution was added to each well. And continuously culturing for 2h, and then measuring the OD value at 450nm in a microplate spectrophotometer.
Cell Viability (Cell Viability) ═ OD experimental/OD control mean values were calculated.
The result is shown in figure 2, the polypeptide CAK18N has obvious effect of promoting the proliferation of liver cells, and the dose-effect relationship is obvious. Compared with the model control group (relative cell activity 0.405 +/-0.044), the medium (relative cell activity 0.567 +/-0.071) and high dose (relative cell activity 0.588 +/-0.053) groups have statistically significant difference (P is represented by P < 0.01) in the promotion effect on the proliferation of the liver cells.
EXAMPLE 3 detection of the Activity of the polypeptide CAK18N in vitro to inhibit hepatocyte apoptosis
The method for detecting the activity of the polypeptide CAK18N in inhibiting the hepatocyte apoptosis in vitro in example 1 comprises the following steps:
human liver cell HL-7702 with cell concentration of 1 × 10 laid on 96-well plate5Each cell/ml, 100. mu.l per well, i.e. 1X 10 cells per well4And (4) respectively.
And adding actinomycin D2(Act D2) of 20ng/mL into each hole, treating for 30min, and treating for 48h by using tumor necrosis factor alpha (TNF-alpha) of 80ng/mL to establish an apoptosis model.
The corresponding polypeptide CAK18N was added to the cells at a final concentration of 0.1, 1, 10. mu.g/ml in a volume of 10. mu.l, and the same volume of PBS was used as a negative control and Epidermal Growth Factor (EGF) at 0.2. mu.g/ml was used as a positive control.
24h after drug treatment, 100. mu.l Caspase-
Reagent (caspase-
3/7Assaypromega, Cat number: g8090) The contents of each well were gently mixed on a shaker at 300-. Incubation was carried out at room temperature (18-22 ℃) for 30 minutes to 3 hours.
The fluorescence value of each sample was measured on a fluorescence Luminometer (Luminometer) (Promega, GloMax bioluminescence detector).
The result is shown in figure 3, the polypeptide CAK18N has the obvious effect of inhibiting the liver cell apoptosis, and the dose-effect relationship is obvious. Compared with a model control group (fluorescence intensity 136576.2 +/-11384), the inhibition effect of the medium (fluorescence intensity 80624.49 +/-3362) and high dose (fluorescence intensity 47641.37 +/-5763) on the hepatocyte apoptosis is statistically significant (P is represented by P < 0.01).
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Sequence listing
<110> Guangzhou Zhicheng medical science and technology Limited
<120> polypeptide CAK18N and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis
<160>1
<170>SIPOSequenceListing 1.0
<210>1
<211>18
<212>PRT
<213> Artificial sequence
<400>1
Cys Lys Ala Gln Gly His Arg Tyr Phe Ser Lys Val Cys Glu Leu Arg
1 5 10 15
Cys Pro
Claims (10)
1. A polypeptide capable of promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis has amino acid sequence identity of 16/18 or more compared with the amino acid sequence shown in SEQ ID NO. 1.
2. The polypeptide of claim 1, wherein the amino acid sequence is set forth in SEQ ID NO 1.
3. The polypeptide of claim 1 or 2, which has a terminal modification, which is an N-terminal acetylation modification or/and a C-terminal amidation modification.
4. Use of the polypeptide of claim 1 or a salt thereof for the manufacture of a medicament for promoting hepatocyte proliferation or treating a disease caused by hepatocyte apoptosis.
5. The use of claim 4, wherein the salt is an acetate, hydrochloride or phosphate salt of the polypeptide.
6. The use of claim 4, wherein the disease caused by apoptosis of liver cells is liver failure, viral hepatitis, liver fibrosis, liver cirrhosis, alcoholic liver disease, non-alcoholic fatty liver disease or autoimmune liver disease.
7. The use of claim 4, wherein the promotion of hepatocyte proliferation is the promotion of liver regeneration in vivo or the promotion of hepatocyte growth in vitro.
8. A medicament for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis, which comprises the polypeptide or a salt thereof according to claim 1.
9. The medicament of claim 8, wherein the disease caused by apoptosis of liver cells is acute liver failure.
10. The medicament of claim 8, wherein the promotion of hepatocyte proliferation is the promotion of liver regeneration in vivo or the promotion of hepatocyte growth in vitro.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911014535.3A CN110713521B (en) | 2019-10-23 | 2019-10-23 | Polypeptide CAK18N and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911014535.3A CN110713521B (en) | 2019-10-23 | 2019-10-23 | Polypeptide CAK18N and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110713521A true CN110713521A (en) | 2020-01-21 |
| CN110713521B CN110713521B (en) | 2022-08-16 |
Family
ID=69213208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911014535.3A Active CN110713521B (en) | 2019-10-23 | 2019-10-23 | Polypeptide CAK18N and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110713521B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109593117A (en) * | 2019-01-11 | 2019-04-09 | 广州领晟医疗科技有限公司 | It is a kind of for the peptide C KA18N of angiogenesis inhibiting and its application |
| CN113845571A (en) * | 2021-11-10 | 2021-12-28 | 华南理工大学 | Active polypeptide for inhibiting growth of liver cancer cells and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180134760A1 (en) * | 2015-09-03 | 2018-05-17 | B. G. Negev Technologies And Applications Ltd. At Ben-Gurion University | ANALOGUES OF VDAC1-DERlVED PEPTIDES |
| CN108676074A (en) * | 2018-05-28 | 2018-10-19 | 广州博瑞佳生物科技有限公司 | A kind of active peptides of hepatic cell growth promotion |
| CN109439612A (en) * | 2018-09-18 | 2019-03-08 | 广州领晟医疗科技有限公司 | Promote hepatocyte growth and/or inhibits the polypeptide and application thereof of hepatocellular apoptosis |
| CN109593117A (en) * | 2019-01-11 | 2019-04-09 | 广州领晟医疗科技有限公司 | It is a kind of for the peptide C KA18N of angiogenesis inhibiting and its application |
-
2019
- 2019-10-23 CN CN201911014535.3A patent/CN110713521B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180134760A1 (en) * | 2015-09-03 | 2018-05-17 | B. G. Negev Technologies And Applications Ltd. At Ben-Gurion University | ANALOGUES OF VDAC1-DERlVED PEPTIDES |
| CN108676074A (en) * | 2018-05-28 | 2018-10-19 | 广州博瑞佳生物科技有限公司 | A kind of active peptides of hepatic cell growth promotion |
| CN109439612A (en) * | 2018-09-18 | 2019-03-08 | 广州领晟医疗科技有限公司 | Promote hepatocyte growth and/or inhibits the polypeptide and application thereof of hepatocellular apoptosis |
| CN109593117A (en) * | 2019-01-11 | 2019-04-09 | 广州领晟医疗科技有限公司 | It is a kind of for the peptide C KA18N of angiogenesis inhibiting and its application |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109593117A (en) * | 2019-01-11 | 2019-04-09 | 广州领晟医疗科技有限公司 | It is a kind of for the peptide C KA18N of angiogenesis inhibiting and its application |
| CN113845571A (en) * | 2021-11-10 | 2021-12-28 | 华南理工大学 | Active polypeptide for inhibiting growth of liver cancer cells and preparation method and application thereof |
| CN113845571B (en) * | 2021-11-10 | 2023-08-15 | 华南理工大学 | Active polypeptide for inhibiting liver cancer cell growth and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110713521B (en) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114644683B (en) | Polypeptide for promoting hepatocyte proliferation and/or inhibiting hepatocyte apoptosis and application thereof | |
| EP2552470B1 (en) | Peptides for promoting angiogenesis and an use thereof | |
| CN110713521B (en) | Polypeptide CAK18N and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis | |
| CN110669126B (en) | Polypeptide GPR5 and application thereof in promoting hepatocyte proliferation and inhibiting hepatocyte apoptosis | |
| US11963997B2 (en) | Anti-tumor polypeptide Bax-BH3, fluorescent polymeric nanomicelle, preparation method and use thereof | |
| CN111533800B (en) | Novel somatotropin-releasing hormone analogous peptide modification and dimerization preparation and application thereof | |
| CN107794280B (en) | Targeted cell-penetrating peptide gene vector and application thereof | |
| KR20190108417A (en) | Dual functional peptide for cell penetration and muscle cell regeneration and use of the same | |
| CN110627866B (en) | Polypeptide RLY4 and application thereof in promoting liver regeneration and inhibiting hepatocyte apoptosis | |
| JP2019531094A (en) | Agonist peptides for adiponectin receptors | |
| JP3761476B2 (en) | Membrane permeation type NFAT inhibitor peptide | |
| CN111249446B (en) | New use of polypeptide and its salt | |
| CN110590929B (en) | Application of TDGF-1 truncated body small molecule polypeptide in anti-hepatic fibrosis | |
| CN100417662C (en) | Peptide for promoting insulin release of frog and its use in production of drugs | |
| WO1999055361A1 (en) | Neovascularization inhibitors | |
| CN109096368B (en) | Polypeptide with antioxidant and liver protecting activities, gene for encoding polypeptide, preparation method and application thereof | |
| CN108017711B (en) | Anti-calcification short peptide and application thereof | |
| CN114426573A (en) | Nur77 phosphorylation derivative peptide and application thereof in preparation of drug for promoting embryo implantation | |
| CN102219850A (en) | New long-acting GLP-1 (glucagonlike peptide-1) compounds | |
| JP5549912B2 (en) | Drugs for polycythemia vera or essential thrombocythemia | |
| CN112891361B (en) | Application of Pubescenoside C in preparation of medicine for preventing and treating myocardial ischemia-reperfusion injury | |
| CN114470162B (en) | Application of GDF6 and over-expression reagent thereof in preparation of myocardial cell protective agent | |
| WO2023227133A1 (en) | Human amylin analog, and derivative and use thereof | |
| CN118344437A (en) | Anti-fibrosis cyclic peptide and application thereof | |
| CN114558115A (en) | Application of ELABELA in improving survival and migration of adipose-derived stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |